Breast Cancer Clinical Trials in Chicago

Showing 201-220 of 704 trials

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

NCT00898131

RATIONALE: Collecting and storing samples of tumor tissue from patients with breast cancer to study in the laboratory may help doctors learn more about cancer. PURPOSE: This phase I study is collecting tissue samples for future research from women undergoing surgery for breast cancer.

Breast Cancer

Northwestern University10,000 participantsStarted Aug 2001

Chicago, Illinois, United States

RECRUITINGPhase 22.2 miles

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

NCT06062498

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.

Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast Cancerv+1 more

Northwestern University174 participantsStarted Sep 2023

Chicago, Illinois, United States

RECRUITINGPhase 12.2 miles

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

NCT05783622

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck+4 more

Janux Therapeutics130 participantsStarted Apr 2023

Duarte, California, United States • Sacramento, California, United States • San Diego, California, United States +15 more locations

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Breast Cancer Trials in Other Cities

A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Proton Radiation for Stage II/III Breast Cancer

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Assessing the Time Demands of Cancer

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Other Conditions in Chicago